The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.
The five-year collaboration brings together Yingli’s experience in medicinal chemistry with MD Anderson’s comprehensive clinical and translational resources to drive existing Yingli therapeutic candidates into four U.S...
Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles...
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover...